Table 1 Preclinical data for anti-CLL-1 antibody-based therapy
Study | Antibody type | In vitro efficacy | Animal model | In vivo efficacy | Adverse effect |
|---|---|---|---|---|---|
Zheng 2019 [41] | Anti-CLL-1-PBD | Highly active against AML cell line and primary AML cells | Mice | Significant decrease in leukemia burden | No weight loss and signs of moribundity |
Cynomolgus monkeys | N/A | Well toleration; welling at injection site; remarkable decrease of granulocyte and monocyte, minimal decrease of RBC; no effect on PLT and lymphocytes | |||
Jiang 2018 [43] | Anti-CLL-1-IQB | Effective to AML cell line and primary AML cell; inhibit LSC colony formation | Mice | Significant decrease in leukemia burden | No effect on engraftment or differentiation of CD34+ cells |
Zhao 2010 [19] | Anti-CLL-1 antibody | Effective to AML cell line and primary AML cells | Mice | Delayed tumor growth | N/A |
Wiersma 2015 [44] | scFvCLL-1:TRAIL | Upregulating TRAIL on granulocytes, improving anti-tumor activity of granulocyte; enhancing ADCC. | N/A | N/A | N/A |
Leong 2017 [1] | Anti-CLL-1/anti–CD3 bispecific antibody | Highly active against CLL-1+ AML cell lines and clinical AML samples, especially for CD3H. | Cynomolgus monkeys | N/A | Vascular shock with CLL-1/CD3H; well toleration with CLL-1/CD3L. Evident decrease of monocyte and granulocyte, early decrease of lymphocyte. |
Lu 2014 [46] | Anti-CLL-1/anti–CD3 bispecific antibody | High cytotoxicity to AML cell lines, modest cytotoxicity to primary AML. | Mice | Elimination of the tumor | No effect on body weight and other status |
Loo 2015 [47] | Anti-CLL-1/anti–CD3 bispecific antibody | Efficiently activating T cells, potent anti-leukemia against primary AML cells | N/A | N/A | N/A |